Iloprost inhalation - Pharmosa Biopharm
Alternative Names: L608; Liposomal iloprost controlled release - Pharmosa BioPharm; Liposomal Iloprost sustained release - Pharmosa BioPharmLatest Information Update: 31 Oct 2024
At a glance
- Originator Pharmosa Biopharm
- Class Alkynes; Anti-ischaemics; Antiplatelets; Peripheral vasodilators; Prostaglandins; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Epoprostenol receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Pulmonary arterial hypertension
- Preclinical Raynaud's disease
Most Recent Events
- 02 Sep 2024 Pharmosa Biopharm completes a phase I trial in Pulmonary arterial hypertension (In volunteers) in Australia (Inhalation) (NCT05938946)
- 12 Jun 2024 Pharmacokinetics data from preclinical trial in Raynaud's disease presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 31 May 2024 Pharmosa Biopharm plans a phase I trial for Pulmonary arterial hypertension (In Volunteers) in New Zealand (Inhalation, solution) (NCT06429930)